Skip to main content

Neutra Corp

corporate_fare Company Profile

Neutra Corp

NTRR·OTC·Life Sciences·CIK 0001512886

Neutra Corp markets and participates in the nutraceutical space, focusing on products derived from natural and organic origins. The company was incorporated in Nevada on January 11, 2011, and reincorporated in Wyoming on August 16, 2019. Neutra Corp plans to research and introduce new technology to the nutraceutical space, which encompasses natural medicine focused on natural remedies and the body's self-healing ability. A key sub-market the company intends to participate in is the medical cannabis market. Neutra Corp intends to outsource manufacturing to a nutraceutical contractor, private labeling all products to be sold under its unique brand. The company's fiscal year ends on January 31. Neutra Corp actively seeks out new technologies and products for the cannabis industry, covering areas such as lighting, dosage devices, pesticide replacements, and plant enhancers. On January 23, 2018, Neutra Corp entered into an agreement with Artillery Labs to sell and market natural nutraceuticals online, specifically its own line of all-natural and legal CBD products, utilizing Artillery Labs' online sales infrastructure. Artillery Labs is to be paid $25,000 upon the successful marketing launch of a product. On August 30, 2019, Neutra Corp acquired all outstanding stock of Vivis Corporation, a Wyoming corporation, from Sydney Jim, the CEO. The purchase price for Vivis was $35,000 cash, plus a royalty of 40 percent of gross revenue until $100,000 is paid, declining to 25 percent until an additional $100,000 has been paid, followed by a 10 percent royalty in perpetuity.

Neutra Corp (OTC:NTRR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 1 item for NTRR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-06-29, rated 7/10.

Recent high-impact activity:

  • Neutra Life Sciences Forms Women's Health JV, Secures New Clinical Trials

Short Interest & Short Volume

On October 1, 2026, 76.6% of NTRR volume reported to FINRA trade-reporting facilities was marked short.

Daily short volume (FINRA facilities)76.6% of 1,435,998 shares on October 1, 2026
4-day average short volume57.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$0.0001 -0.00% today
52-week range · as of 2026-06-29 $0.000001 – $0.0003
Market cap
$291.79K
Volume
278 (0.0× avg)
3-mo avg 2.7M
Live data · 2026-10-05 02:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NTRR - Latest Insights

NTRR
Jun 29, 2026, 3:29 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.0001
Real-time Price: $0.0001 info
Change: Low Volume info
Market Cap: $291.79K info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets